

CITATION REPORT

List of articles citing

Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?

DOI: 10.1007/s40259-019-00357-2
BioDrugs, 2019, 33, 437-446.

Source: <https://exaly.com/paper-pdf/73129247/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?". <i>BioDrugs</i> , 2019 , 33, 581-582	7.9	1
8	Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00604	3.1	6
7	Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. <i>BioDrugs</i> , 2020 , 34, 225-233	7.9	4
6	Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. <i>BioDrugs</i> , 2021 , 35, 379-387	7.9	1
5	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	18.79	3
4	Pharmacokinetics of Biologics. 2020 , 125-145		1
3	Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References. <i>AAPS Journal</i> , 2021 , 24, 3	3.7	
2	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. <i>BioDrugs</i> ,	7.9	0
1	Biosimilars: Harmonizing the Approval Guidelines. 2022 , 2, 171-195		0